Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
nerve agent
|
| gptkbp:absorptionRoutes |
gptkb:skin
inhalation ingestion |
| gptkbp:antidote |
gptkb:pralidoxime
atropine |
| gptkbp:aroma |
none or faint
|
| gptkbp:chemicalClass |
organophosphate
|
| gptkbp:color |
colorless to amber
|
| gptkbp:developedBy |
gptkb:United_Kingdom
|
| gptkbp:effectOnHumans |
death
respiratory failure convulsions |
| gptkbp:example |
gptkb:VE
gptkb:VM gptkb:VX VG VS |
| gptkbp:firstSynthesized |
1950s
|
| https://www.w3.org/2000/01/rdf-schema#label |
V-series nerve agent
|
| gptkbp:mechanismOfAction |
gptkb:acetylcholinesterase_inhibitor
|
| gptkbp:prohibits |
gptkb:Chemical_Weapons_Convention
|
| gptkbp:relatedTo |
gptkb:G-series_nerve_agent
|
| gptkbp:riskFactor |
persistent in environment
|
| gptkbp:stateAtRoomTemperature |
gptkb:water
|
| gptkbp:toxicity |
highly toxic
|
| gptkbp:usedIn |
chemical warfare
|
| gptkbp:bfsParent |
gptkb:VX_nerve_agent
|
| gptkbp:bfsLayer |
7
|